Last reviewed · How we verify

Epsilon-aminocaproic acid administered — Competitive Intelligence Brief

Epsilon-aminocaproic acid administered (Epsilon-aminocaproic acid administered) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifibrinolytic agent. Area: Hematology / Hemostasis.

phase 3 Antifibrinolytic agent Plasminogen / Plasmin Hematology / Hemostasis Small molecule Live · refreshed every 30 min

Target snapshot

Epsilon-aminocaproic acid administered (Epsilon-aminocaproic acid administered) — Montefiore Medical Center. Epsilon-aminocaproic acid inhibits fibrinolysis by blocking plasminogen activation and plasmin activity, thereby reducing excessive bleeding.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Epsilon-aminocaproic acid administered TARGET Epsilon-aminocaproic acid administered Montefiore Medical Center phase 3 Antifibrinolytic agent Plasminogen / Plasmin
Tranexamic Acid (TXA) Tranexamic Acid (TXA) NYU Langone Health marketed Antifibrinolytic agent Plasminogen / Plasmin
Tranexamic Acid Injectable Product Tranexamic Acid Injectable Product The University of Texas Health Science Center at San Antonio marketed Antifibrinolytic agent Plasminogen / Plasmin
Tranexamic Acid (IV) Tranexamic Acid (IV) Samsung Medical Center marketed Antifibrinolytic agent Plasminogen / Plasmin
Tranexamic Acid Pill Tranexamic Acid Pill Henry Ford Health System marketed Antifibrinolytic agent Plasminogen / Plasmin
Tranexamic acid + Standard of Care Tranexamic acid + Standard of Care Pfizer marketed Antifibrinolytic agent Plasminogen / Plasmin
Tranexamic Acid (Topical) Tranexamic Acid (Topical) Total Definer Research Group marketed Antifibrinolytic agent Plasminogen / Plasmin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifibrinolytic agent class)

  1. Montefiore Medical Center · 2 drugs in this class
  2. Pfizer · 2 drugs in this class
  3. Hamilton Health Sciences Corporation · 2 drugs in this class
  4. Chinese Academy of Medical Sciences, Fuwai Hospital · 1 drug in this class
  5. Henry Ford Health System · 1 drug in this class
  6. Massachusetts General Hospital · 1 drug in this class
  7. NYU Langone Health · 1 drug in this class
  8. Mount Sinai Hospital, Canada · 1 drug in this class
  9. Dr. Lutfi Kirdar Kartal Training and Research Hospital · 1 drug in this class
  10. Carlos A Acosta-Olivo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Epsilon-aminocaproic acid administered — Competitive Intelligence Brief. https://druglandscape.com/ci/epsilon-aminocaproic-acid-administered. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: